Kinnov-Therapeutics Announces Positive Phase 2 Outcome: Key Milestone with Lead Drug KT-110 for Alcohol Use Disorder.

Kinnov-Therapeutics has reached a key clinical milestone for treatment of Alcohol Use Disorder with a Phase 2 clinical study for its game changing drug KT-110. Alcoholism is a major public health issue with a strong unmet medical need.

Link to online article

Kinnov Therapeutics Announces Positive Phase 2 Outcome: Key Milestone with Lead Drug KT-110 for Alcohol Use Disorder